Key Takeaways
- Three senior Oklo executives collectively disposed of more than $21M worth of stock on April 1, with CEO Jacob DeWitte and COO Caroline Cochran each selling approximately $10M.
- DeWitte has maintained a consistent selling pattern since the start of the year, unloading shares at prices between roughly $50 and $100.
- CNBC’s Jim Cramer delivered harsh criticism, stating Oklo lacks meaningful revenue prospects and isn’t yet a functioning commercial operation.
- The company’s recent quarterly results disappointed investors, posting a loss of $0.27 per share against analyst expectations of -$0.17.
- While analysts maintain a “Moderate Buy” rating overall, the average price target stands at $84.30, with multiple firms reducing their targets recently.
On April 1, 2026, three senior Oklo executives executed stock sales exceeding $21 million in total value, all transactions occurring through pre-established Rule 10b5-1 trading arrangements.
CEO and co-founder Jacob DeWitte disposed of shares at weighted average prices spanning $48.41 to $51.20, generating proceeds of $10,069,852. Following this transaction, DeWitte maintains direct ownership of 691,533 Class A shares, while retaining indirect control over more than 20 million additional shares.
Co-founder and COO Caroline Cochran executed sales worth an identical $10,069,852, with transaction prices ranging between approximately $47.99 and $51.79 per share. Her remaining direct stake stands at 658,039 shares.
CFO Richard Bealmear unloaded 16,342 shares at $51.08 each, netting $834,749. His post-transaction holdings total 386,008 Class A shares.
Each of these transactions was executed under pre-arranged 10b5-1 trading plans, regulatory mechanisms designed to shield executives from insider trading allegations.
However, the recent sales represent merely the latest chapter in DeWitte’s ongoing divestment strategy. Since January, he has consistently sold Oklo shares at various price points, including transactions near $112, $75, and $63 per share. His cumulative sales over recent months have generated proceeds in the tens of millions.
The April 1 transaction alone—spanning 200,000 shares across two separate sales—reduced his direct ownership position by 17.58%.
Wall Street Commentator Delivers Harsh Assessment
The executive stock sales occurred against a backdrop of sharp criticism from CNBC personality Jim Cramer. During a recent broadcast, Cramer offered a blunt assessment: “Oklo, while not a science project, has very little prospects for making any money any time in the future that we think is important for a stock.”
This wasn’t Cramer’s first critical commentary on Oklo. Earlier in January, he characterized the company as “not a commercial enterprise,” acknowledging nuclear power’s potential while arguing that established players like GE Vernova—with operational commercial facilities—hold superior positioning compared to Oklo at present.
Financial Performance Falls Short of Expectations
Regarding financial fundamentals, Oklo disclosed a quarterly loss of $0.27 per share in its latest earnings report, falling short of the analyst consensus estimate calling for a loss of $0.17 per share—a miss of $0.10.
The analyst community remains cautiously optimistic overall, though price projections have undergone downward revisions. UBS reduced its target from $95 to $60 while assigning a neutral stance. Needham lowered its forecast from $135 to $73, and Canaccord adjusted downward from $175 to $125. Cantor Fitzgerald maintained its overweight rating with a $122 price objective.
The consensus analyst price target currently registers at $84.30, accompanied by a “Moderate Buy” rating. The breakdown includes two Strong Buy recommendations, nine Buy ratings, six Hold positions, and two Sell ratings.
Oklo shares have traded within a 12-month band of $17.42 to $193.84. The stock’s 50-day moving average sits at $64.62, while the 200-day moving average stands at $93.16.
